<DOC>
	<DOCNO>NCT00098345</DOCNO>
	<brief_summary>The purpose open label , two stage , phase II study evaluate efficacy tolerability ZD6474 patient locally advance metastatic hereditary medullary thyroid carcinoma .</brief_summary>
	<brief_title>Efficacy Tolerability ZD6474 Patients With Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Locally advanced hereditary medullary thyroid cancer Signed inform consent One measurable lesion Brain metastasis spinal cord compression Specific laboratory range Specific heart problem Prior chemotherapy and/or radiation therapy Participation trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Caprelsa ( vandetanib )</keyword>
	<keyword>ZD6474</keyword>
</DOC>